

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Where application of: Raju, Jeyaseelan  
 Application No.: 10/626,173 Group No.: 1652  
 Filed: July 24, 2003 Examiner: Monshipouri, Maryam  
 For: NOVEL CARC PROTEIN AND NUCLEIC ACID MOLECULES AND USES  
 THEREFOR

**Confirmation No. 1880**

**Mail Stop Issue Fee  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450**

**TRANSMITTAL**

1. Transmitted herewith for this application is/are:
  - a. This Transmittal (2 pages - in duplicate);
  - b. Transmittal of Payment of Issue Fee (2 pages - in duplicate);
  - c. Part B - Fees Transmittal (1 page - in duplicate);
  - d. Amendment After Allowance (7 pages);
  - e. Letter Accompanying Amendment After Allowance (2 pages);
  - f. Authorization to Act in a Representative Capacity for Mario Cloutier (2 pages);
  - g. Statement of Limited Recognition under 37 CFR § 11.9 (b) for Mario Cloutier (1 page);  
and
  - h. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 21, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.



Practitioner's Docket No. MPI98-105P1RCP2DV1M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Raju, Jeyaseelan		
Application No.:	10/626,173	Group No.:	1652
Filed:	July 24, 2003	Examiner:	Monshipouri, Maryam
For:	NOVEL CARK PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR		

**Mail Stop Issue Fee**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY**

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier  
Limited Recognition Under 37 CFR §11.9(b)  
Customer Number 30405 or  
Millennium Pharmaceuticals, Inc.  
40 Landsdowne Street  
Cambridge, MA 02139

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: July 21, 2005

Sean Hunziker  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI98-105P1RCP2DV1M

**FEE DEFICIENCY**

3. Papers contained herein authorize payment of Issue Fees. It is believed no additional fees are required, however, if any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.

4. Correspondence Address  
Direct all future correspondence to:

**Customer Number 30405**  
OR  
Intellectual Property Department  
MILLENNIUM PHARMACEUTICALS, INC.  
40 Landsdowne Street  
Cambridge, MA 02139

July 21, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier  
Limited Recognition Under 37 C.F.R. §11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820

**This is not a Power of Attorney to the above-named practitioner.**

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.


Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.

**SIGNATURE of Practitioner of Record**

July 21, 2005

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By   
Jean M. Silveri  
Registration No. 39,030  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone – (617) 679-7336  
Facsimile – (617) 551-8820




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: December 29, 2006**

  
\_\_\_\_\_  
Harry I. Moatz  
Director of Enrollment and Discipline



Practitioner's Docket No. MPI98-105P1RCP2DV1M

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Raju, Jeyaseelan  
Application No.: 10/626,173                      Group No.: 1652  
Filed: July 24, 2003                      Examiner: Monshipouri, Maryam  
For: NOVEL CARC PROTEIN AND NUCLEIC ACID MOLECULES AND USES  
THEREFOR

**Confirmation No.: 1880**

**Mail Stop Issue Fee**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**LETTER ACCOMPANYING AMENDMENT AFTER ALLOWANCE**  
**(37 C.F.R. Section 1.312)**

1. Please make the amendments shown in the attached papers in this application in the

- ☐ abstract.
- ☒ specification.
- ☐ drawings.
- ☐ claims.

2. Type of amendment:

- ☒ Correction of formal matters  
As shown in the remarks of the attached paper, these (1) are needed for proper disclosure or

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
**37 C.F.R. SECTION 1.8(a)**                      **37 C.F.R. SECTION 1.10\***

- ☒ with sufficient postage as first class mail.                      ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 21, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI98-105P1RCP2DV1M**

protection of the invention and (2) require no substantial amount of additional work on the part of the PTO.

☐ Other (affects the disclosure, the scope of any claim or adds a claim) (M.P.E.P. Section 714.16, 7th ed.)

As shown in the remarks in the attached supplemental page(s), there is stated the reason (1) why the amendment is needed, (2) why the proposed amended or new claims require no additional search or examination, (3) why the claims are patentable, and (4) why they were not earlier presented.

3. The issue fee:

☐ has not been paid.  
☒ is paid separately herewith.  
☐ was paid on \_\_\_\_\_ .

4. Request for Entry of Amendments:

(a) ☒ Because the issue fee has been paid or is paid herewith, the applicant hereby requests entry of the attached amendments. (37 C.F.R. Section 1.312).

5. Fees:

☒ Please charge Account 501668 for any fees that may be required by the filing of this paper.

July 21, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By 

Mario Cloutier  
Limited Recognition Under 37 C.F.R. §11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820